Sep 17, 2009 9:19am EDT Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
Jul 23, 2009 6:00pm EDT R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Jul 23, 2009 12:00pm EDT Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
Jul 09, 2009 6:00am EDT Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Jul 08, 2009 9:00pm EDT Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
